Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.90 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | MMP3 | P08254 | 1/20 | 0.67 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.67 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | KIF11 | P52732 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.50 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.50 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tannin Pyrogallol SCHEMBL3486430 | 1.00 | ALDH1A1 (0.90) | ALDH1A1TAAR1MAPK1CYP1A2CYP3A4 | |
| SCHEMBL29713847 | 1.00 | ALDH1A1 (0.90) | ALDH1A1TAAR1MAPK1CYP1A2CYP3A4 | |
| Tannin Pyrogallol SCHEMBL11689471 | 1.00 | ALDH1A1 (0.90) | ALDH1A1TAAR1MAPK1CYP1A2CYP3A4 | |
| SCHEMBL18674172 | 1.00 | ALDH1A1 (0.90) | ALDH1A1TAAR1MAPK1CYP1A2CYP3A4 | |
| Biphenyl SCHEMBL895675 | 1.00 | ALDH1A1 (0.90) | ALDH1A1TAAR1MAPK1CYP1A2CYP3A4 | |
| Tannin Pyrogallol SCHEMBL21448 | 1.00 | ALDH1A1 (0.90) | ALDH1A1TAAR1MAPK1CYP1A2CYP3A4 | |
| SCHEMBL1991754 | 1.00 | ALDH1A1 (0.90) | ALDH1A1TAAR1MAPK1CYP1A2CYP3A4 | |
| SCHEMBL143471 | 1.00 | ALDH1A1 (0.90) | ALDH1A1TAAR1MAPK1CYP1A2CYP3A4 | |
| SCHEMBL827097 | 1.00 | ALDH1A1 (0.90) | ALDH1A1TAAR1MAPK1CYP1A2CYP3A4 | |
| Tannin Pyrogallol SCHEMBL27699073 | 1.00 | ALDH1A1 (0.90) | ALDH1A1TAAR1MAPK1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160387-B1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2014-05-14 | — | — | EP | disclosed |
| US-8598175-B2 | Heteroarylamide pyrimidone derivatives | SANOFI (FR) | 2013-12-03 | — | — | US | disclosed |
| US-8592437-B2 | Heteroarylamide pyrimidone compounds | SANOFI (FR) | 2013-11-26 | — | — | US | disclosed |
| EP-2162443-B1 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| US-20130001081-A1 | Colorimetric or electrochemical mercury and trace metal detector | DAVIS JOHN PERRIN (US) | 2013-01-03 | — | — | US | disclosed |
| US-8198287-B2 | Substituted heteroaryl pyridopyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-06-12 | — | — | US | disclosed |
| WO-2011142777-A1 | CYCLOOCTATETRAENE-BASED CATHODE FOR ELECTROCHEMICAL CELLS | PDB POWER SYSTEMS, LLC (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20100087449-A1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | disclosed |
| US-20100081677-A1 | HETEROARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-01 | — | — | US | disclosed |
| EP-2162443-A2 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sanofi-Aventis (FR) | 2010-03-17 | — | — | EP | disclosed |
| EP-2160387-A2 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | Sanofi-Aventis (FR) | 2010-03-10 | — | — | EP | disclosed |
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-12-10 | — | — | US | disclosed |
| EP-2121635-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008155666-A2 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155668-A2 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| EP-1992624-A1 | Heteroarylamide pyrimidone compounds | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
| EP-1992621-A1 | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008078196-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | GSK3B, GSK3A, GSKIP | ALDH1A1 1709/4885TAAR1 4132/4885MAPK1 829/4885 |
| US-20100087449-A1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | DHFR, DPYD, HPRT1 | ALDH1A1 281/4885TAAR1 1344/4885MAPK1 2410/4885 |
| US-20100081677-A1 | HETEROARYLAMIDE PYRIMIDONE DERIVATIVES | DHFR, DPYD, HPRT1 | ALDH1A1 270/4885TAAR1 1322/4885MAPK1 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.